Interestingly, EZH2 (the catalytic subunit of PRC2 complex) enhances tumorigenesis and is overexpressed in poor-prognostic CLL patients in association with upregulation of PI3K/AKT through IGFR1 and MYC (38) and epigenetically silences the tumor suppressor miR-125 (39). This evidence concerns the gene AKT1 and neoplasm.